» Articles » PMID: 38067276

Understanding the Role of Radio-Sensitizing Nanoparticles in Enhancing Pathologic Response in Soft Tissue Sarcomas

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2023 Dec 9
PMID 38067276
Authors
Affiliations
Soon will be listed here.
Abstract

High-atomic-number (Z) nanoparticles produce a cascade of low-energy secondary electrons and characteristic X-rays when ionized by X-ray irradiation. These secondary particles deposit their energy in the vicinity of the nanoparticles and, provided that the latter are selectively accumulated within tumor cells, this results in increased DNA damage and tumor cell deaths. This study reviews the utilization of high-Z nanoparticles in the treatment of soft tissue sarcomas (STS). Both in vitro and in vivo experiments demonstrated that the dose is enhanced by approximately 1.2 when polyethelyne glycol (PEG)-modified gold nanoparticles, and from 1.4 to 1.8 when hafnium oxide nanoparticles (NBTXR3, Nanobiotix SA, France) are introduced into tumor cells and activated by X-ray beams. In a phase 2/3 clinical trial investigating the therapeutic benefit of using nanoparticles in preoperative external beam radiotherapy for locally advanced STS, the proportion of patients with a pathological complete response in their resected tumor was doubled when NBTXR3 nanoparticles were used. Additionally, a higher percentage of patients with complete tumor resection was observed in the NBTXR3 plus radiotherapy group. Similar toxicity profiles were found for both the NBTXR3 plus radiotherapy and the radiotherapy alone patient groups. The incorporation of radio-sensitizing nanoparticles in the preoperative radiotherapy of STS could enhance treatment outcomes.

Citing Articles

Ultrahypofractionated Versus Normofractionated Preoperative Radiotherapy for Soft Tissue Sarcoma: A Multicenter, Prospective Real-World-Time Phase 2 Clinical Trial.

Heesen P, Di Lonardo M, Ciobanu-Caraus O, Schelling G, Zwahlen D, Bode-Lesniewska B Cancers (Basel). 2024; 16(23).

PMID: 39682249 PMC: 11640059. DOI: 10.3390/cancers16234063.


What Is the Prognostic Value of the Pathologic Response after Neoadjuvant Radiotherapy in Soft Tissue Sarcoma? An Institutional Study Using the EORTC-STBSG Response Score.

Stergioula A, Kormas T, Kokkali S, Memos N, Pantelis E, Pouloudi D Cancers (Basel). 2024; 16(20).

PMID: 39456543 PMC: 11506461. DOI: 10.3390/cancers16203449.

References
1.
Kuncic Z, Lacombe S . Nanoparticle radio-enhancement: principles, progress and application to cancer treatment. Phys Med Biol. 2017; 63(2):02TR01. DOI: 10.1088/1361-6560/aa99ce. View

2.
Grabellus F, Podleska L, Sheu S, Bauer S, Pottgen C, Kloeters C . Neoadjuvant treatment improves capsular integrity and the width of the fibrous capsule of high-grade soft-tissue sarcomas. Eur J Surg Oncol. 2012; 39(1):61-7. DOI: 10.1016/j.ejso.2012.10.009. View

3.
Schuemann J, Bagley A, Berbeco R, Bromma K, Butterworth K, Byrne H . Roadmap for metal nanoparticles in radiation therapy: current status, translational challenges, and future directions. Phys Med Biol. 2020; 65(21):21RM02. DOI: 10.1088/1361-6560/ab9159. View

4.
Bonvalot S, Rutkowski P, Thariat J, Carrere S, Ducassou A, Sunyach M . NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2-3, randomised, controlled trial. Lancet Oncol. 2019; 20(8):1148-1159. DOI: 10.1016/S1470-2045(19)30326-2. View

5.
Chavda V, Balar P, Patel S . Nanotheranostics-based Management of Head and Neck Cancer. Nanotheranostics. 2023; 7(2):202-209. PMC: 9925351. DOI: 10.7150/ntno.81724. View